Can a $200M Injection Rewrite the Rules on Schizophrenia?

When a little-known clinical-stage firm aligns with the FDA and secures nine-figure funding on the same day, smart money pays attention.

With a new Phase 3 trial underway and regulatory resubmission in sight, this company could be rewriting the future of mental health.

Imagine doubling your money by this time next year — without chasing hype or guessing trends.

Our analysts just identified 5 companies showing the same early patterns that have historically preceded major stock moves.

Each combines strong fundamentals with technical signals that could lead to serious upside.

No guarantees, of course — but past reports using this method have uncovered multiple triple-digit winners.

The best part?

You can access the full list right now, completely free.

Hurry — the window to download closes at MIDNIGHT TONIGHT.

[Get Your Free Copy Now]

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Wall Street was mixed, with the S&P 500 backed by strong corporate earnings and optimism around a potential government shutdown resolution, while Alphabet’s drop on OpenAI browser concerns capped broader gains.

Warner Bros. Discovery (NASDAQ: WBD) just confirmed it’s reviewing unsolicited takeover bids, kicking off what could be Hollywood’s next billion-dollar drama.

You’re watching one of the most iconic studios on Earth weigh whether to sell the house or remodel it.

The review covers every option from breaking up divisions to a full-scale acquisition.

That means your favorite franchises—HBO hits, DC heroes, and cinematic universes—could soon have new corporate parents.

The Streaming Struggle Gets Real

Even with Harry Potter and Looney Tunes in its arsenal, Warner Bros. Discovery has been fighting gravity in a brutal streaming market.

Revenue from old-school TV is falling, while subscriber growth just isn’t keeping pace with the debt it inherited.

You might see this as another entertainment shuffle, but it’s more like a rescue mission for a company that helped define what you watch.

The media landscape is changing faster than a scene cut.

A Blockbuster Deal in the Making

If the sale goes through, this could be one of the biggest reshuffles in modern entertainment.

Potential buyers see untapped value locked inside decades of IP gold.

You’re witnessing an inflection point that could redefine how global content giants are built, sold, and streamed.

Somewhere in this chaos, a new Hollywood storyline is being written.

Blackstone (NYSE: BX) just wrote one of the year’s biggest checks, teaming up with TPG to take Hologic (NASDAQ: HOLX) private in an $18.3 billion deal.

You’re watching private equity move from boardrooms into hospital labs, chasing growth in places that actually save lives.

The buyout cements healthcare as Wall Street’s new obsession, where diagnostics and data meet long-term returns.

For Hologic, this means fresh capital, sharper focus, and less quarterly noise from public markets.

Why Blackstone Loves the Lab Coat

This isn’t just financial engineering—it’s strategy with a pulse.

Hologic’s dominance in breast and cervical cancer testing makes it a rare blend of stable demand and technological innovation.

You might not realize how big women’s health diagnostics have become, but private equity does.

The predictable margins and defensible patents make this one of the safest bets in medtech right now.

The Bigger Picture Behind the Buyout

Blackstone is building an empire of essential industries—from servers to scalpels.

This acquisition plants a flag in healthcare’s most resilient corner, where science meets recurring revenue.

If you’re tracking where smart money is heading next, this move says it all.

Blackstone is not only acquiring companies but also investing in the future of modern medicine.

Crypto history was made — and most people missed it.

Congress just passed the GENIUS Act, the first major crypto law in U.S. history. Trump signed it immediately, calling America the “crypto capital of the planet.”

This law changes everything. For the first time, crypto has federal clarity — not case-by-case enforcement.

That means:

Institutions are flooding in, and the next wave of opportunity is forming fast.

Get your FREE Crypto Revolution book and see how to position yourself early — includes $788 in bonuses (just cover s&h).

Claim your copy now.

The regulatory revolution has begun.

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

Walmart (NYSE: WMT) is throwing down the gauntlet in the holiday price wars with a $4-per-person Thanksgiving basket, its lowest cost since the program launched.

You get the full spread—turkey, pie crust, potatoes, and even mac and cheese without your wallet needing recovery time afterward.

The move hits right where it counts: family budgets.

Walmart is betting that you’ll remember who made your holiday possible when prices everywhere else still feel like a bad joke.

The Price-Cut Power Play

This isn’t random generosity; it’s retail chess.

Walmart is outmaneuvering competitors like Aldi and Kroger by turning affordability into a brand weapon.

If you’re feeling the pinch from inflation, this deal feels less like a discount and more like a lifeline.

It’s how Walmart builds emotional loyalty in an economy where every dollar counts.

The Bigger Game Behind the Basket

Walmart’s low-cost feast doubles as a flex of supply chain muscle.

Its ability to trim prices while protecting margins shows just how far ahead it is in retail logistics.

You might see a cheaper turkey, but it's a business strategy disguised as mashed potatoes.

In the battle for your grocery cart this holiday, Walmart just set the table, and everyone else is scrambling for a seat.

👉 Click here to get our closing report to your cell for free!

Minerva Neurosciences, Inc [NERV] $6.41 (+140.98%)

Minerva soared after securing up to $200 million in new funding and aligning with the FDA on its Phase 3 trial and NDA resubmission for roluperidone.

Sionna Therapeutics Inc [SION] $42.50 (+31.99%)

Sionna advanced after launching a landmark Phase 2a trial testing its first-in-class CFTR stabilizer in combination with Trikafta.

Mayville Engineering Company [MEC] $15.70 (+20.68%)

Mayville jumped after multiple analysts raised price targets and upgraded the stock, with Citigroup and Craig Hallum forecasting strong upside.

Neuphoria Therapeutics Inc [NEUP] $4.85 (-68.50%)

Neuphoria plunged after its anxiety drug BNC210 failed to meet primary and secondary endpoints in a Phase 3 trial, forcing the company to halt the program and begin a strategic review.

Cleveland-Cliffs Inc [CLF] $13.39 (-17.27%)

Cleveland‑Cliffs slipped after Wells Fargo downgraded the stock, calling last week’s 22% surge on rare‑earth optimism an overreaction unsupported by fundamentals.

Critical Metals Corp [CRML] $16.27 (-16.91%)

Critical Metals declined after Jim Cramer urged investors to take profits, cooling enthusiasm that had fueled recent rare‑earth‑driven gains.

Markets don’t wait. The biggest moves often start quietly — and only those who act early benefit.

That’s why we’ve just released a brand-new FREE report: 7 Best Stocks for the Next 30 Days.

These aren’t random picks.

Less than 5% of all companies met the strict criteria to make this list.

Each stock was carefully screened for earnings strength, momentum, and catalysts that could spark fast gains.

[Download your free copy now] and see the 7 stocks set to lead.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.